Skip to main content
Premium Trial:

Request an Annual Quote

PierianDx, University Hospital of Augsburg Tailoring NGS Workflow to European Market

NEW YORK – PierianDx said Tuesday that it is teaming with University Hospital of Augsburg in Germany to customize an interpretation and reporting workflow for Thermo Fisher Scientific's AmpliSeq for Illumina Myeloid and Focus assays.

University Hospital of Augsburg, which already runs AmpliSeq Myeloid and Focus tests, will create the workflow on the PierianDx Clinical Genomics Workspace as it looks to expand its next-generation sequencing and precision oncology programs. The hospital and St. Louis-based PierianDx said that the workflow will be tailored to the European market, following European Society for Medical Oncology guidelines, European Medicines Agency drug labels, and databases of available clinical trials on the continent.

"As we provide streamlined interpretation and supporting solutions for leading assay manufacturers, it's imperative that we acknowledge region-specific needs of the market," Rakesh Nagarajan, PierianDx's founder, president, and chief technology and visionary officer, said in a statement.

"We are happy to work with PierianDx to optimize the workflow and pioneer one of the first region-specific reporting solutions for the AmpliSeq assays," added Sebastian Dintner, head of molecular pathology at the German hospital. "By doing so, we will be able to accomplish our mission of expanding our precision medicine offerings to provide advanced cancer care for our patients."